You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Baxter
Express Scripts
McKinsey
Dow

Last Updated: February 28, 2021

DrugPatentWatch Database Preview

Azacitidine - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for azacitidine and what is the scope of patent protection?

Azacitidine is the generic ingredient in three branded drugs marketed by Accord Hlthcare, Actavis Llc, Cipla, Dr Reddys, Eurohlth Intl Sarl, Lupin Ltd, Meitheal, Mylan Institutional, Natco Pharma Ltd, Shilpa Medicare, Celgene, and Celgene Corp, and is included in twelve NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Azacitidine has sixty-nine patent family members in thirty-four countries.

There are fifteen drug master file entries for azacitidine. Thirteen suppliers are listed for this compound.

Summary for azacitidine
International Patents:69
US Patents:1
Tradenames:3
Applicants:12
NDAs:12
Drug Master File Entries: 15
Suppliers / Packagers: 13
Bulk Api Vendors: 109
Clinical Trials: 420
Patent Applications: 7,340
Formulation / Manufacturing:see details
Drug Prices: Drug price trends for azacitidine
What excipients (inactive ingredients) are in azacitidine?azacitidine excipients list
DailyMed Link:azacitidine at DailyMed
Drug Prices for azacitidine

See drug prices for azacitidine

Recent Clinical Trials for azacitidine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Aprea TherapeuticsPhase 1
Treadwell Therapeutics, IncPhase 1/Phase 2
The First Affiliated Hospital of Soochow UniversityPhase 2

See all azacitidine clinical trials

Pharmacology for azacitidine
Medical Subject Heading (MeSH) Categories for azacitidine

US Patents and Regulatory Information for azacitidine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Corp ONUREG azacitidine TABLET;ORAL 214120-001 Sep 1, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Lupin Ltd AZACITIDINE azacitidine POWDER;INTRAVENOUS, SUBCUTANEOUS 210748-001 Feb 27, 2019 DISCN No No   Start Trial   Start Trial   Start Trial
Actavis Llc AZACITIDINE azacitidine POWDER;INTRAVENOUS, SUBCUTANEOUS 208216-001 Apr 29, 2016 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Colorcon
Mallinckrodt
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.